Search Results - "Plöckinger, U"

The German National Action League for people with rare diseases: translating the three tiers center system into active co-operation, a one center experience by Plöckinger, U, Ziagaki, A

“…In 2009 the European Commission called for National action plans (NAP) to improve the care for persons with rare diseases. Germany set up a NAP in 2013…”
Get full text

Long-term growth hormone (GH) replacement of adult GH deficiency (GHD) benefits the heart by Ziagaki, A, Blaschke, D, Haverkamp, W, Plöckinger, U

“…Objective Growth hormone (GH) deficiency is related to increased cardiovascular mortality. We studied clinical status, concentration of amino-terminal-pro…”
Get full text

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms by Caplin, Martyn, Sundin, Anders, Nillson, Ola, Baum, Richard P, Klose, Klaus J, Kelestimur, Fahrettin, Plöckinger, Ursula, Papotti, Mauro, Salazar, Ramon, Pascher, Andreas

Get more information

2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease by Plöckinger, U, Prasad, V, Ziagaki, A, Tiling, N, Poellinger, A

“…Pompe disease (PD) is an autosomal recessive, lysosomal storage disease due to a mutation of the acid α-glucosidase (GAA) gene. In adult patients, PD is…”
Get full text

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) by Plöckinger, U, Rindi, G, Arnold, R, Eriksson, B, Krenning, E P, de Herder, W W, Goede, A, Caplin, M, Oberg, K, Reubi, J C, Nilsson, O, Delle Fave, G, Ruszniewski, P, Ahlman, H, Wiedenmann, B

Get more information

Medical Therapy of Acromegaly by U. Plöckinger

“…This paper outlines the present status of medical therapy of acromegaly. Indications for permanent postoperative treatment, postirradiation treamtent to bridge…”
Get full text

An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease by Kulessa, M., Weyer‐Menkhoff, I., Viergutz, L., Kornblum, C., Claeys, K. G., Schneider, I., Plöckinger, U., Young, P., Boentert, M., Vielhaber, S., Mawrin, C., Bergmann, M., Weis, J., Ziagaki, A., Stenzel, W., Deschauer, M., Nolte, D., Hahn, A., Schoser, B., Schänzer, A.

“…Aims Pompe disease is caused by pathogenic mutations in the alpha 1,4‐glucosidase (GAA) gene and in patients with late onset Pome disease (LOPD),…”
Get full text

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations by Sundin, Anders, Vullierme, Marie-Pierre, Kaltsas, Gregory, Plöckinger, Ursula

Get more information

Biotherapy by Plöckinger, U., MD, Wiedenmann, B., MD

“…This review gives an introduction to the classification and staging of neuroendocrine tumors, as the prognostic implications of these classifications influence…”
Get full text

DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours by Plöckinger, U, Hoffmann, U, Geese, M, Lupp, A, Buchfelder, M, Flitsch, J, Vajkoczy, P, Jakob, W, Saeger, W, Schulz, S, Dohrmann, C

“…ObjectiveSomatostatin analogues (SSA) reduce autonomous GH secretion by activating somatostatin receptors (sst) 2 and 5 in 50–60% of acromegalic patients…”
Get full text

Treatment of gastroenteropancreatic neuroendocrine tumors by Plöckinger, U, Wiedenmann, B

“…Neuroendocrine tumors are rare; thus, individual experience with the diagnosis and treatment of these tumors is mostly low, except in specialized centers. For…”
Get full text

Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR by Schopohl, J, Strasburger, C J, Caird, D, Badenhoop, K, Beuschlein, F, Droste, M, Plöckinger, U, Petersenn, S

“…To assess the efficacy of different dosing intervals of lanreotide, Somatuline Autogel® (Lan-ATG) 120 mg in patients with acromegaly, previously treated with…”
Get more information

Prevalence of aspirin resistance in patients with type 2 diabetes by Fateh-Moghadam, S, Plöckinger, U, Cabeza, N, Htun, P, Reuter, T, Ersel, S, Gawaz, M, Dietz, R, Bocksch, W

“…Aspirin resistance has been recognised to occur in patients with cardiovascular disease and is associated with poor clinical prognosis. The purpose of the…”
Get full text

Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours by Amthauer, H, Denecke, T, Rohlfing, T, Ruf, J, Böhmig, M, Gutberlet, M, Plöckinger, U, Felix, R, Lemke, A J

“…The objective was the evaluation of single photon emission computed tomography (SPECT) with integrated low dose computed tomography (CT) in comparison with a…”
Get full text

Problems of diabetes management in the immigrant population in Germany by Plöckinger, U, Topuz, M, Langer, M, Reuter, T

“…Abstract Aim To compare prospectively the effect of diabetes management in the immigrant and the native population in Berlin, Germany. Methods Diabetes…”
Get full text

OR01-5 Prevalence of AIP gene mutations in young patients with acromegaly by Schöfl, C, Honegger, J, Droste, M, Grussendorf, M, Finke, R, Plöckinger, U, Klingmuller, D, Jaursch-Hancke, C, Tönjes, A, Schneidewind, S, Flitsch, J, Mayr, B, Hoeppner, W, Schopohl, J

Get full text

Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit? by Amthauer, H, Ruf, J, Böhmig, M, Lopez-Hänninen, E, Rohlfing, T, Wernecke, K-D, Plöckinger, U, Gutberlet, M, Lemke, A-J, Steinmüller, T, Wiedenmann, B, Felix, R

“…This study evaluated the use of image fusion in the preoperative staging of neuroendocrine tumors (NET) of the pancreas and the gastrointestinal tract (GIT)…”
Get full text

Multi-centre phase IV trial to investigate the immunogenicity of a new liquid formulation of recombinant human growth hormone in adults with growth hormone deficiency by Johannsson, G., Nespithal, K., Plöckinger, U., Alam, V., McLean, M.

“…Purpose To investigate whether a new liquid formulation of recombinant human growth hormone (r-hGH) induces the production of binding antibodies (BAbs) in…”
Get full text

Oxaliplatin plus 5-fluorouracil/folinic acid as palliative treatment for progressive malignant gastrointestinal neuroendocrine carcinomas by Pape, U., Tiling, N., Bartel, C., Plöckinger, U., Wiedenmann, B.

“…Abstract only 14074 Background: Oxaliplatin in combination with 5-fluorouracil and folinic acid is an antitumoral agent with relatively low toxicity and…”
Get full text

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide by Kwekkeboom, Dik J, Krenning, Eric P, Scheidhauer, Klemens, Lewington, Val, Lebtahi, Rachida, Grossman, Ashley, Vitek, Pavel, Sundin, Anders, Plöckinger, Ursula

Get more information